Analysts forecast that Elevance Health will add approximately 450,000 net members in Q4 2025, representing 3.2% year-over-year growth in its commercial and government segments. Premium revenue is expected to climb by 8.5% sequentially, driven by a 7.8% rate increase in commercial lines and expansion in Medicaid membership. Observers note that elevated enrollment in Medicare Advantage plans—anticipated at 250,000 new members—will contribute roughly $1.1 billion in incremental premium revenue for the quarter.

For Q4, consensus calls for a medical loss ratio of 84.7%, up from 83.2% in Q3, reflecting elevated hospital utilization and specialty drug costs. Administrative expense ratio is projected to hold steady at 6.1%, as higher technology and care-management investments offset efficiency gains. Combined, these metrics imply a total underwriting ratio near 90.8%, pressuring underwriting income relative to premium growth.

Elevance’s operating income for the quarter is forecast at $3.35 billion, implying an operating margin of 7.2% on expected revenues of $46.5 billion. This margin estimate marks a 40 basis-point decline from the prior quarter, attributable to higher medical expenses and incremental administrative outlays. Earnings before interest and taxes are projected to range between $3.2 billion and $3.5 billion, in line with the mid-range of analyst models.

Free cash flow for Q4 is estimated at $2.6 billion, bolstered by favorable working capital timing and lower benefit reserve builds. Elevance is expected to propose $1.2 billion in share repurchases and maintain its quarterly dividend at $1.25 per share. Management’s preliminary guidance for full-year 2026 anticipates revenue growth of 7% to 9% and an operating margin of 7.0% to 7.5%, underscoring confidence in margin stabilization despite near-term cost headwinds.